According to the market research firm Frost & Sullivan, the main drivers to impact the healthcare industry this year will be big data analytics, artificial intelligence (AI), and mHealth. mHealth, or mobile health, is a general term for the use of mobile phones and other wireless technology in medical care. As we. as a society, become increasingly more digital so does the healthcare industry.
One of the largest transformational shifts seen in the healthcare industry is the increase of personal informatics. The growing networks of connected health technologies such as wearables, telemedicine, artificial intelligence and virtual reality which support a more personalized health experience.
Another report by Grandview Research that supports this idea indicates, “with the combination of artificial and human intelligence data analytics, which offer wide opportunities to further customize medical approaches, the demand for these tools is anticipated to increase over the forecast period”.
With the global healthcare market forecast to hit $53.65 billion by 2025, companies seeking to develop innovative approaches to traditional care offerings may create opportunities to investors looking to healthcare stocks.
Premier Health Group, Inc. (PHGRF) (PHGI) recently acquired all of the outstanding securities of Cloud Practice Inc., a medical software company. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients and provides the company with an underlying platform to help empower and streamline patient-doctor interaction.
“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO.
Premier Health also announced it is formally entering the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers and expects to provide additional updates later this quarter. The company is also moving forward with a binding LOI to acquire two cash flow positive Vancouver pharmacies and anticipates the acquisition to close in or about Q2 2019 and recently entered into a strategic partnership with China’s 360 Health, whereby Premier will be providing second opinion services by connecting 360 Health’s patients in China with doctors in Canada both remotely and in person.
CAS Medical Systems, Inc. (CASM), a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain, has entered into a definitive merger agreement to be acquired by Edwards Lifesciences Corporation (EW), a global leader in patient-focused innovations for structural heart disease and critical care monitoring. The acquisition is expected to close in the second quarter of 2019.
Edwards will acquire CAS Medical in an all-cash transaction for $2.45 per share of Common Stock, or an equity value of approximately $100 million. Edwards has a pending 510(k) clearance in the United States for a smart cable and software module, which enables compatibility between CAS Medical’s FORE-SIGHT sensor and the HemoSphere advanced hemodynamic monitoring platform. This technology was developed as a result of a collaboration between Edwards and CASMED and has received a CE Mark in Europe.
“We are pleased with this opportunity to bring together CASMED’s expertise in brain and tissue oxygenation monitoring with Edwards’ long history of leadership in hemodynamic monitoring,” said Thomas M. Patton, President and CEO. “We are confident that the combination of these technologies will result in an important measurement tool for physicians that can empower them to improve care.”
Trevena, Inc. (TRVN) has regained Nasdaq listing compliance. The company annouced that it will be featured as a presenting company at the 21st Annual BIO CEO & Investor Conference, sponsored by the Biotechnology Innovation Organization today Tuesday, February 12, 2019 in New York.
The company recently entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of 10,000,000 shares of its common stock at an offering price of $1.00 per share, in a registered direct offering, for gross proceeds of $10.0 million. Trevena intends to use the net proceeds from the offering primarily for the development of its lead product candidate, oliceridine, and for other general corporate purposes.
Trevena is a biopharmaceutical company that focuses on the development and commercialization of new and innovative treatment options for patients in pain and has investigational drug candidates: IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the treatment of acute migraine, and TRV734 for pain and/or management of opioid dependence.
This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.
Biotech Breakroom 